secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-08-07T01:27:49+00:00
Accession:  0001104659-26-092246
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for advanced melanoma
--------------------------------------------------------------------------------

- FDA approved TUDRIQEV (vusolimogene oderparepvec-wtpg) + nivolumab on Aug 6, 2026 for unresectable advanced melanoma after anti-PD-1 progression.
- IGNYTE trial: ORR 24.2%, median duration of response 14.1 months in 91-patient efficacy-evaluable population.
- Confirmatory Phase 3 trial IGNYTE-3 (NCT06264180) ongoing; approval contingent on verification of clinical benefit.
- Population included 80% Stage 4 disease, 54% PD-L1 negative, 45% lung and 24% liver lesions; treatment well tolerated.
- Replimune now commercial stage; launching ReplimuneConnect Plus patient access, reimbursement and financial support program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926092246/0001104659-26-092246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926092246/tm2622487d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer